Table 1:
Selected mouse models of SARS-CoV infection show effect of age and ACE2 expression
| Mouse Strain | Genotype | Age at Infection | Virus Strain | Morbidity | Mortality | Notes | Reference |
|---|---|---|---|---|---|---|---|
| BALB/c | WT | 4 weeks | Urbani | Some | No | Oral and intranasal inoculation | 64 |
| BALB/c | WT | 4–6 weeks | Urbani | No | No | 65 | |
| C57BL/6 | WT | 5–6 weeks | Urbani | Some | No | 66 | |
| C57BL/6 | beige | 5–6 weeks | Urbani | Some | No | Lack NK cells | 66 |
| C57BL/6 | Cd1−/− | 5–6 weeks | Urbani | Some | No | Lack NK cells | 66 |
| C57BL/6 | Rag1−/− | 5–6 weeks | Urbani | No | No | Lack T and B cells | 66 |
| BALB/c | WT | 6 weeks | MA15 | Yes | Yes | Mouse-adapted virus strain | 67 |
| BALB/c | WT | 8 weeks | Urbani | No | No | 68 | |
| C57BL/6 or BALB/c | hACE2 expressing | 8–20 weeks | Urbani | Yes | Yes | CAG promoter (ubiquitous) | 69 |
| BALB/c | WT | 12–14 months | Urbani | Yes | No | 70 | |
| BALB/c | WT | 12–14 months | Urbani | Yes | No | 68 | |
| 129SvEv | WT | ND | Toronto-2 | Some | No | 71 | |
| 129SvEv | Stat1−/− | ND | Toronto-2 | Yes | No | Disrupted interferon signaling | 71 |
| C56BL/6 | hACE2 expressing | ND | Urbani | Yes | Yes | K18 promoter (epithelial cells) | 72 |